# OnCo record swog-s1826 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/swog-s1826/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "swog-s1826", "NCT03907488" ;
  schema:name "SWOG S1826"@en ;
  schema:description "Immunotherapy plus chemotherapy beat the previous best regimen with far less nerve damage, in the first Hodgkin trial to enrol children and adults together; approved March 2026."@en ;
  schema:url <https://onco.cc/trials/swog-s1826/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03907488>, <https://www.targetedonc.com/view/fda-approves-nivolumab-plus-avd-for-classical-hodgkin-lymphoma> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2019-08-29" ;
  onco:related <https://onco.cc/collections/src-targeted-oncology/> ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/doxorubicin/> ;
  onco:companies <https://onco.cc/companies/swog/>, <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:people <https://onco.cc/people/kara-kelly/>, <https://onco.cc/people/alex-herrera/> .